Table 1.
Basal characteristics of patients, in the total group and in subgroup according to antidiabetic treatment. DPP4i = dipeptidyl-peptidase-4 inhibitors; GLP-1 = glucagon-like peptide-1receptor agonists; SGLT2i= sodium-glucose cotransporter-2 inhibitors; SU = sulfonylureas; IIEF = International Index of Erectile Function; DM = diabetes mellitus; BMI = body mass index; CV = cardiovascular. a p < 0.05 vs. total group. b p < 0.05 vs. insulin. c p < 0.05 vs. total group. d p < 0.05 vs. SGLT2i and GLP-1.
| Total Group No. 163 |
Diet No. 21 |
Metformin No. 51 |
DPP4i No. 19 |
SGLT2i No. 25 |
GLP1a No. 20 |
Insulin No. 23 |
SU No. 4 |
|
|---|---|---|---|---|---|---|---|---|
|
Age (years; mean ± SD, range) |
62.9 ± 9.3 20–75 |
62.1 ± 11.3 33–75 |
64.1 ± 9.9 20–75 |
64.4 ± 8.3 48–75 |
61.9 ± 9.4 41–74 |
62.3 ± 7.6 48–72 |
60.7 ± 9.4 39–75 |
66.0 ± 4.9 59–70 |
|
preDM (yes; no., %) |
15/163 9.2% |
15/21 71.4% a |
0/51 0% |
0/19 0% |
0/25 0% |
0/20 0% |
0/23 0% |
0/4 0% |
| IIEF-5 (mean ± SD) | 14. ± 5.8 | 14.9 ± 6.1 | 15.5 ± 5.7 | 15.5 ± 4.5 | 13.2 ± 5.9 | 16.7 ± 4.7 b | 12.6 ± 6.4 | 14.8 ± 9.3 |
| IIEF-5 groups | ||||||||
| No ED (> 21) | 21 (12.8%) | 2 (9.5%) | 8 (15.7%) | 2 (10.5%) | 2 (8.0%) | 4 (20.0%) | 3 (13.0%) | 0 (0%) |
| ED (5–21) | 142(87.2%) | 19 (90.5%) | 43 (84.3%) | 17 (89.5%) | 23 (92.0%) | 16 (80.0%) | 20 (87.0%) | 4 (100%) |
| Mild ED (17–21) | 48 (29.4%) | 8 (38.1%) | 16 (31.4%) | 7 (36.8%) | 4 (16.0%) | 8 (40.0%) b | 2 (8.7%) | 3 (75.0%) |
| Mild/Moderate (12–16) | 44 (27.0%) | 6 (28.6%) | 13 (25.5%) | 6 (31.6%) | 8 (32.0%) | 4 (20.0%) | 7 (30.4%) | 0 (0%) |
| Moderate ED (8–11) | 30 (18.4%) | 2 (9.5%) | 8 (15.7%) | 3 (15.8%) | 7 (28.0%) | 4 (20.0%) | 6 (26.1%) | 0 (0%) |
| Severe ED (5–7) | 20 (12.3%) | 3 (14.3% | 6 (11.8%) | 1 (5.3%) | 4 (16.0%) | 0 (0%) | 5 (21.3%) | 1 (25.0%) |
| BMI | 28.4 ± 4.6 | 28.1 ± 3.5 | 28.1 ± 3.6 | 26.4 ± 3.1 | 29.8 ± 5.9 | 29.3 ± 5.6 | 28.1 ± 5.0 | 30.4 ± 2.1 |
| (Kg/m2; mean ± SD, range) | 18.4–45.9 | 19.6–36.7 | 19.6–36.7 | 18.4–32.7 | 21.1–44.3 | 22.5–45.9 | 19–38.6 | 28.1–33.0 |
| BMI groups (n,%) | ||||||||
| Normal weight | 36 (22.1%) | 6 (28.6%) | 8 (15.7%) | 6 (31.6%) | 5 (20.0%) | 5 (25.0%) | 6 (26.1%) | 0 (0%) |
| Overweight | 72 (44.2%) | 9 (42.8%) | 27 (52.9%) | 10 (52.6) | 10 (40.0%) | 7 (35.0%) | 7 (30.4%) | 2 (50.0%) |
| Obese | 55 (33.7%) | 6 (28.6%) | 16 (31.4%) | 3 (15.8%) | 10 (40.0%) | 8 (40.0%) | 10 (43.5%) | 2 (50.0%) |
| Physical activity | 64/163 | 8/21 | 22/51 | 7/19 | 8/25 | 2/20 | 14/23 | 3/4 |
| (yes, no., %) | 39.4% | 38.1% | 43.1% | 36.8% | 32.0% | 10.0% | 60.9% b | 60.9% |
| Smoking habits | ||||||||
| No (no., %) | 53 (32.5%) | 9 (42.9%) | 23 (45.1%) | 1 (5.3%) | 6 (24.0%) | 9 (45.0%) | 3 (13.0%) | 2 (50.0%) |
| Yes (no., %) | 34 (20.9%) | 4 (19.0%) | 5 (9.8%) | 7 (36.8%) | 6 (24.0%) | 2 (10.0%) | 10 (43.5%) c | 0 (0%) |
| In the past (no., %) | 76 (46.6%) | 8 (38.1%) | 23 (45.1%) | 11 (57.9%) | 13 (52.0%) | 9 (45.0%) | 10 (43.5%) | 2 (50.0%) |
| Family history of DM (no., %) | 54/163 74.2% |
11/21 52.4% |
38/51 74.5% |
13/19 68.4% |
19/25 76.0% |
17/20 85.0% |
20/23 87.0% |
4/4 100% |
|
DM duration (years; no., %) |
10.9 ± 8.3 0–40 |
5.7 ± 5.1 0–15 c |
7.2 ± 6.6 0–30 |
13.2 ± 9.2 1–34 |
9.6 ± 6.6 0–25 |
12.9 ± 6.9 4–30 |
17.7 ± 8.9 2–40 c |
12.5 ± 11.9 4–30 |
|
Treatment duration (mean ± SD) |
3.7 ± 3.1 | 2.0 ± 1.3 | 4.5 ± 3.7 d | 4.5 ± 2.9 | 2.1 ± 1.4 | 2.9 ± 2.4 | 5.1 ± 3.8 | 4.5 ± 2.9 |
|
CV comorbidities (no., %) |
152 93.3% |
19 90.5% |
49 96.1% |
17 89.5% |
25 100% |
19 95.0% |
19 82.6% |
4 100% |
|
Dyslipidemia (no., %) |
121 74.2% |
14 66.7% |
39 76.5% |
16 84.2% |
18 75.0% |
14 70.0% |
16 69.6% |
4 100% |
| HbA1c (%; mean ± SD, range) | 7.1 ± 1.3 5–16 |
6.0 ± 0.6 5.0–6.8 c |
6.5 ± 0.8 5.5–9.4 |
7.2 ± 0.8 6.0–9.0 |
7.3 ± 0.9 5.5–9.6 |
7.4 ± 0.8 5.8–8.3 |
8.2 ± 2.3 5.2–16.0 c |
6.4 ± 0.8 5.6–7.2 |
|
Total Cholesterol (mg/dL; mean ± SD, range) |
160.2 ± 37.5 73–338 |
181.3 ± 47.0 140–338 |
157.2 ± 33.9 97–226 |
153.1 ± 42.4 73–242 |
165.4 ± 36.2 94–226 |
147.8 ± 31.1 89–214 |
166.3 ± 34.9 117–237 |
124.0 ± 36.8 98–150 |
|
Triglycerides (mg/dL; mean ± SD, range) |
135.8 ± 69.1 23–388 |
124.3 ± 47.7 37–223 |
128.6 ± 61.3 50–353 |
136.2 ± 79.5 60–388 |
164.2 ± 86.9 52–379 |
139 ± 65.5 51–259 |
127.0 ± 74.2 23–283 |
121.0 ± 36.8 98–150 |
|
HDL Cholesterol (mg/dL; mean ± SD, range) |
47.6 ± 12.4 23–105 |
51.5 ± 9.3 33–65 |
48.7 ± 12.0 26–80 |
47.8 ± 19.1 24–105 |
44.8 ± 8.4 31–65 |
45.3 ± 7.5 32–61 |
49.0 ± 14.8 27–81 |
38.5 ± 21.9 23–54 |
|
LDL Cholesterol (mg/dL; mean ± SD, range) |
85.5 ± 36.1 14–238 |
114.9 ± 43.2 62.3–238.8 |
87.4 ± 32.9 14.8–157 |
81.3 ± 35.8 18.4–174 |
88.9 ± 39.6 37.8–145.6 |
77.1 ± 28.9 17.4–125 |
97.3 ± 38.3 38.0–178.2 |
61.3 ± 17.4 49–73.6 |
| Total Testosterone (ng/mL; mean ± SD, range) | 4.0 ± 1.8 0.3–11.5 |
4.0 ± 1.6 1.0–7.9 |
4.2 ± 1.7 1.7–8.8 |
4.6 ± 2.8 1.9–11.5 |
3.7 ± 1.7 1.5–7.1 |
3.3 ± 2.1 0.3–5.9 |
3.9 ± 1.5 0.9–5.6 |
2.6 ± 0.2 2.5–2.8 c |